Daiwa Raises KEYMED BIO-B Price Target to HK$110, Reaffirming Buy Call

Deep News

5 hours ago

Daiwa has released a research report stating that KEYMED BIO-B (02162) 2026 first-half results broadly aligned with its previous profit alert and the firm's estimates. Management has raised the 2026 sales guidance for Stapokibart to 850 million yuan.

Daiwa has reaffirmed its "Buy" rating on the stock, lifting the target price from HK$101 to HK$110. The firm has cut its 2026 earnings per share forecast for KEYMED BIO-B by 19%, but raised its 2027 and 2028 earnings per share forecasts by 65% and 128%, respectively. This adjustment reflects a shift in the recognition of milestone payments from the Ouro acquisition, which will now be spread over multiple years instead of being concentrated in 2026. At the same time, the 2026 revenue forecast has been increased by 6%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1174192289"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174192289\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174192289?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-23 12:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174192289","market":"sg","top_or_hot":-1,"title":"Daiwa Raises KEYMED BIO-B Price Target to HK$110, Reaffirming Buy Call","media":"Deep News","content":"<p>Daiwa has released a research report stating that <b>KEYMED BIO-B</b> (02162) 2026 first-half results broadly aligned with its previous profit alert and the firm's estimates. Management has raised the 2026 sales guidance for Stapokibart to 850 million yuan.<br><br>Daiwa has reaffirmed its \"Buy\" rating on the stock, lifting the target price from HK$101 to HK$110. The firm has cut its 2026 earnings per share forecast for <b>KEYMED BIO-B</b> by 19%, but raised its 2027 and 2028 earnings per share forecasts by 65% and 128%, respectively. This adjustment reflects a shift in the recognition of milestone payments from the Ouro acquisition, which will now be spread over multiple years instead of being concentrated in 2026. At the same time, the 2026 revenue forecast has been increased by 6%.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Daiwa Raises KEYMED BIO-B Price Target to HK$110, Reaffirming Buy Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaiwa Raises KEYMED BIO-B Price Target to HK$110, Reaffirming Buy Call\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-08-23 12:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Daiwa has released a research report stating that <b>KEYMED BIO-B</b> (02162) 2026 first-half results broadly aligned with its previous profit alert and the firm's estimates. Management has raised the 2026 sales guidance for Stapokibart to 850 million yuan.<br><br>Daiwa has reaffirmed its \"Buy\" rating on the stock, lifting the target price from HK$101 to HK$110. The firm has cut its 2026 earnings per share forecast for <b>KEYMED BIO-B</b> by 19%, but raised its 2027 and 2028 earnings per share forecasts by 65% and 128%, respectively. This adjustment reflects a shift in the recognition of milestone payments from the Ouro acquisition, which will now be spread over multiple years instead of being concentrated in 2026. At the same time, the 2026 revenue forecast has been increased by 6%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1174192289","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174192289","pubTimestamp":1787460029,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Daiwa has released a research report stating that KEYMED BIO-B (02162) 2026 first-half results broadly aligned with its previous profit alert and the firm's estimates. Management has raised the 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B","BK1583":"高瓴概念","EWH":"香港ETF-iShares MSCI","BK1587":"次新股","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"大和将 KEYMED BIO-B 目标价上调至 110 港元，重申买入看涨期权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWH":1,"02162":1},"content_text":"Daiwa has released a research report stating that KEYMED BIO-B (02162) 2026 first-half results broadly aligned with its previous profit alert and the firm's estimates. Management has raised the 2026 sales guidance for Stapokibart to 850 million yuan.Daiwa has reaffirmed its \"Buy\" rating on the stock, lifting the target price from HK$101 to HK$110. The firm has cut its 2026 earnings per share forecast for KEYMED BIO-B by 19%, but raised its 2027 and 2028 earnings per share forecasts by 65% and 128%, respectively. This adjustment reflects a shift in the recognition of milestone payments from the Ouro acquisition, which will now be spread over multiple years instead of being concentrated in 2026. At the same time, the 2026 revenue forecast has been increased by 6%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}